Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers.
Nome ME, Euceda LR, Jabeen S, Debik J, Bathen TF, Giskeødegård GF, Taskén KA, Maelandsmo GM, Halvorsen B, Yndestad A, Borgen E, Garred Ø, Aukrust P, Ueland T, Engebraaten O, Kristensen VN, Tekpli X.
Nome ME, et al. Among authors: debik j.
Int J Cancer. 2020 Jan 1;146(1):223-235. doi: 10.1002/ijc.32638. Epub 2019 Oct 8.
Int J Cancer. 2020.
PMID: 31444972
Free article.
Clinical Trial.